ISRCTN26181691已完成未知
Weekly intensive versus standard chemotherapy in untreated small cell lung cancer (SCLC) patients with good prognosis
Cancer Research UK (CRUK) (UK)0 个研究点目标入组 0 人开始时间: 2001年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically proven SCLC
- •2. Age 75 or under
- •3. Either limited disease or extensive disease in the good prognostic category. That is have both of the following characteristics, Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 and alkaline phosphatase <1.5 upper limit of normal range
- •4. Adequate renal function
- •5. No previous malignancy, except non-melanomatous skin cancer
- •6. No previous chemotherapy or radiotherapy
- •7. No medical contraindications to treatment
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
Dose-intensive weekly combination chemotherapy (cisplatin, vincristine, doxorubicin and etoposide) followed by cisplatin-etoposide therapy with concurrent thoracic irradiation: evaluation of a new treatment for limited-disease small-cell lung cancer.JPRN-C000000145West Japan Oncology Group20
已完成
1 期
Phase I/II study of weekly chemotherapy consisting of 5-FU, leucovorin, and Paclitaxel (FLTAX) in patients with metastatic or recurrent gastric cancer.Patients with metastatic or recurrent gastric cancerJPRN-UMIN000000502ational Cancer Center Hospital, Gastrointestinal Oncology Division35
进行中（未招募）
1 期
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with Follicular LymphomaHigh tumor burden Follicular LymphomaMedDRA version: 24.0Level: LLTClassification code 10080213Term: In situ follicular lymphomaSystem Organ Class: 100000004864EUCTR2020-003277-22-ITFONDAZIONE ITALIANA LINFOMI ONLUS602
尚未招募
2 期
comparison of 2 schedules of chemotherapy in concurrent chemoradiation in head and neck cancerCTRI/2013/05/003703Regional Cancer CentreTrivandrum100
撤回
不适用
The impact of 18 weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC) on skeletal muscle composition of female breast cancer patientscachexialoss of muscle mass10006291NL-OMON37832Maxima Medisch Centrum13